Press release
Lawsuit filed for Investors in shares of CytomX Therapeutics, Inc. (NASDAQ: CTMX)
An investor, who purchased shares of CytomX Therapeutics, Inc. (NASDAQ: CTMX), filed a lawsuit in the U.S. District Court for the Northern District of California over alleged violations of Federal Securities Laws by CytomX Therapeutics, Inc..Investors who purchased shares of CytomX Therapeutics, Inc. (NASDAQ: CTMX) have certain options and for certain investors are short and strict deadlines running. Deadline: July 20, 2020. NASDAQ: CTMX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
San Francisco, CA based CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States.
The Company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. CytomX's lead product candidates in the clinical stage include, among others, CX-072 and CX-2009.
CytomX Therapeutics, Inc has been evaluating CX-072 in its "PROCLAIM" series clinical program for several years. For example, the PROCLAIM-CX-072-001 clinical trial was designed to assess the tolerability and preliminary antitumor activity of multiple doses of CX-072 as a monotherapy or as a combination therapy with ipilimumab (which Bristol-Myers Squibb Company markets under the brand name Yervoy) or vemurafenib (which Roche markets under the brand name Zelboraf) in patients with advanced, unresectable solid tumors or lymphoma. CytomX Therapeutics, Inc also began conducting a Phase 2 clinical trial called PROCLAIM-CX-072-002, which was initiated in October 2019 and is an open-label, multi-center clinical trial evaluating CX-072 in combination with ipilimumab in patients with unresectable or metastatic melanoma.
Likewise, CystomX had been evaluating CX-2009 under its own "PROCLAIM" brand clinical program. This program includes the PROCLAIM-CX-2009-001 clinical trial, which is a Phase 1/2 trial evaluating the tolerability and preliminary antitumor activity of CX-2009 as a monotherapy, which CytomX initiated in June 2017. This clinical program also proceeded in multiple parts--Parts A and A2, which are monotherapy dose escalation studies; and Part B, which is a Phase 2 expansion study of CX-2009 monotherapy at 7 mg/kg administered every three weeks in up to 40 patients with hormone receptor (ER, PR) positive, HER2 negative breast cancer, which Defendants announced in December 2019 based on the tolerability and activity data from Part A and A2 of the study.
On May 13, 2020, CytomX Therapeutics, Inc made available abstracts for the Company's clinical presentations for CX-072 and CX-2009. Results from the PROCLAIM-CX-072 clinical program showed a response rate of 8.8%, compared to a response rate of 18.5% in patients receiving the combination of CX-072 and ipilimumab. Meanwhile, results from the PROCLAIM-CX-2009 clinical program showed "evidence" of clinical activity at doses at least 4 mg/kg 3x/week, but also suggested a significantly higher rate of serious or greater treatment-related toxicity to the eyes at dose equivalents at least 8 mg/kg 3x/week.
Shares of CytomX Therapeutics, Inc. (NASDAQ: CTMX) declined from $15.32 per share on May 12, 2020, to as low as $8.61 per share on May 15, 2020.
The plaintiff claims that between May 17, 2018, and May 13, 2020, the defendants failed to disclose to investors that CytomX had downplayed issues with CX-072's efficacy observed in the PROCLAIM-CX-072 clinical program, that CytomX had similarly downplayed issues with CX-2009's efficacy and safety observed in the PROCLAIM-CX-2009 clinical program, and that as a result, the Company's public statements were materially false and misleading at all relevant times.
Those who purchased shares of CytomX Therapeutics, Inc. (NASDAQ: CTMX) have certain options and should contact the Shareholders Foundation.
Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lawsuit filed for Investors in shares of CytomX Therapeutics, Inc. (NASDAQ: CTMX) here
News-ID: 2061338 • Views: …
More Releases from Shareholders Foundation
![Investigation announced for Investors who lost money with shares of Dayforce Inc (NYSE: DAY)](https://cdn.open-pr.com/L/9/L903110236_g.jpg)
Investigation announced for Investors who lost money with shares of Dayforce Inc …
An investigation was announced for investors of Dayforce Inc (NYSE: DAY) shares over potential securities laws violations by Dayforce Inc.
Investors who purchased shares of Dayforce Inc (NYSE: DAY), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Dayforce Inc regarding its business, its prospects and its operations were materially…
![Investigation announced for Investors who lost money with shares of Dril-Quip, Inc. (NYSE: DRQ)](https://cdn.open-pr.com/L/8/L827381306_g.jpg)
Investigation announced for Investors who lost money with shares of Dril-Quip, I …
An investigation was announced for investors of Dril-Quip, Inc. (NYSE: DRQ) shares over potential securities laws violations by Dril-Quip, Inc.
Investors who purchased shares of Dril-Quip, Inc. (NYSE: DRQ), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Dril-Quip, Inc. (NYSE: DRQ) concerning whether a series…
![Investigation announced for Investors in shares of Xiao-I Corporation (NASDAQ: AIXI) over potential Wrongdoing](https://cdn.open-pr.com/L/8/L822549698_g.jpg)
Investigation announced for Investors in shares of Xiao-I Corporation (NASDAQ: A …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Xiao-I Corporation.
Investors who purchased shares of Xiao-I Corporation (NASDAQ: AIXI) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Xiao-I Corporation directors breached their fiduciary duties and caused damage to the company and its shareholders.
China based Xiao-I Corporation,…
![Investigation announced for Investors in shares of DLocal Limited (NASDAQ: DLO) over potential Wrongdoing](https://cdn.open-pr.com/L/8/L822647959_g.jpg)
Investigation announced for Investors in shares of DLocal Limited (NASDAQ: DLO) …
An investigation was announced for investors in shares of DLocal Limited (NASDAQ: DLO) concerning potential breaches of fiduciary duties by certain directors and officers of DLocal Limited.
Investors who are investors in DLocal Limited (NASDAQ: DLO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for investors in NASDAQ: DLO stocks follows a lawsuit filed against…
More Releases for CytomX
Investigation announced for Long-Term Investors in CytomX Therapeutics, Inc. (NA …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors of CytomX Therapeutics, Inc.
Investors who are current long term investors in CytomX Therapeutics, Inc. (NASDAQ: CTMX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors inNASDAQ: CTMX stocks follows a lawsuit filed against CytomX Therapeutics, Inc. over…
Deadline on July 20, 2020, coming up in Lawsuit filed for Investors in shares of …
The Shareholders Foundation announced that a deadline is coming up on July 20, 2020 in the lawsuit filed for certain investors of CytomX Therapeutics, Inc. (NASDAQ: CTMX) over alleged securities laws violations by CytomX Therapeutics, Inc.
Investors who purchased shares of CytomX Therapeutics, Inc. (NASDAQ: CTMX) have certain options and there are strict and short deadlines running. Deadline: July 20, 2020. NASDAQ: CTMX stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Oncology Drugs Market 2019 | Industry Insight By Key Players Roche, Johnson and …
Oncology drugs and medications have become a blooming business for players in the pharmaceutical industry. Major pharmaceutical companies are focused on manufacturing and development of oncology drug. Market players have oncology drugs in pipeline, which are expected to be in the market as potential medications in near future. Also, the global oncology market is expected to gain a significant traction with the increasing prevalence of cancer. According to the National…
Global Oncology Drugs Market is Growing at a Remarkable CAGR 2018-2026 By Global …
Roche is a world leader in oncology, which is engaged in developing new approaches for advanced cancer treatment. Roche operates in two segments, which includes pharmaceuticals and diagnostics with annual sales of US$ 39.1 Bn and US$ 11.5 Bn respectively. Roche is at the forefront of cancer immunotherapy with ten investigational drug candidates currently in the clinical development phase. In 2016, the company entered into 10 new clinical collaboration agreements…
Global Oncology Drugs Market - Competitive Analysis, Growth And Revenue Analysis …
Oncology drugs and medications have become a blooming business for players in the pharmaceutical industry. Major pharmaceutical companies are focused on manufacturing and development of oncology drug. Market players have oncology drugs in pipeline, which are expected to be in the market as potential medications in near future. Also, the global oncology market is expected to gain a significant traction with the increasing prevalence of cancer. According to the National…
Global Oncology Drugs Market Analysis Report, Regional Outlook with Key Players …
Coherent Market Insights has announced the addition of the “Global Oncology Drugs Market Size Status and Forecast 2026”, The report classifies the global Oncology Drugs Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth.
This report studies the global Oncology Drugs Speaker market, analyzes and researches the Oncology Drugs Speaker development status and forecast in North America, Europe,…